Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset |
BMC Cardiovascular Disorders |
Chua W, Easter CL, Guasch E, Sitch A, Casadei B, Crijns HJGM, Haase D, Hatem S, Stefan Kääb, Mont L, Schotten U, Sinner MF, Hemming K, Deeks JJ, Kirchhof P and Fabritz L |
May, 2019 |
10.1186/s12872-019-1105-4
|
ElectroMap: High-throughput open-source software for analysis and mapping of cardiac electrophysiology |
Scientific Reports |
O’Shea C, Holmes AP, Yu TY, Winter J, Wells SP, Correia J, Boukens BJ, DeGroot JD, Chu GS, Li X, Ng GA, Kirchhof P, Fabritz L, Rajpoot K, Pavlovic D |
February, 2019 |
10.1038/s41598-018-38263-2
|
Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation |
European Heart Journal |
Chua W, Purmah Y, Cardoso VR, Gkoutos GV, Tull SP, Neculau G, Thomas MR, Kotecha D, Lip GYH, Kirchhof P, Fabritz L |
January, 2019 |
10.1093/eurheartj/ehy815
|
T-wave inversion in young athletes: Should we check their bones or their identity card? The quest for precision medicine |
European Journal of Preventive Cardiology |
Guasch E, Sanz-de la Garza M, Mont L |
December, 2018 |
10.1177/2047487318820665
|
Determining the best approach to reduce the impact of exercise-induced atrial fibrillation: prevention, screening, or symptom-based treatment? |
Expert Review of Cardiovascular Therapy |
San Antonio R, Guasch E, Tolosana JM & Mont L |
December, 2018 |
10.1080/14779072.2019.1550720
|
Assessment of right ventricular sympathetic dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy: An 123I-metaiodobenzylguanidine SPECT/CT study |
Journal of Nuclear Cardiology |
Todica A, Siebermair J, Schiller J, Zacherl MJ, Fendler WP, Massberg S, Bartenstein P, Cyran CC, Kääb S, Hacker M, Wakili R, Lehner S |
December, 2018 |
10.1007/s12350-018-01545-3
|
Agatston score of the descending aorta is independently associated with coronary events in a low-risk population |
Open Heart |
Dudink EAMP, Peeters FECM, Altintas S, Heckman LIP, Haest RJ, Kragten H, Kietselaer BLJH, Wildberger J, Luermans JGLM, Weijs B, Crijns HJGM |
November, 2018 |
10.1136/openhrt-2018-000893
|
Rationale and design of a multicentre, randomized, placebo‐controlled trial of mirabegron, a Beta3‐adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3‐left ventricular hypertrophy |
ESC Heart Failure |
Pouleur AC, Anker S, Brito D, Brosteanu O, Hasenclever D, Casadei B, Edelmann F, Filippatos G, Gruson D, Ikonomidis I, Lhommel R, Mahmod M, Neubauer S, Persu A, Gerber BL, Piechnik S, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M et al. |
October, 2018 |
10.1002/ehf2.12306
|
Differentiation and quantification of fibrosis, fat and fatty fibrosis in human left atrial myocardium using ex vivo MRI |
PLOS One |
Bouazizi K, Rahhal A, Kusmia S, Evin M, Defrance C, Cluzel P, Berthet M, Atassi F, Leprince P, Lebreton G, Kachenoura N, Hatem SN, Redheuil A |
October, 2018 |
10.1371/journal.pone.0205104
|
The VAMP-associated protein VAPB is required for cardiac and neuronal pacemaker channel function |
The FASEB Journal |
Silbernagel N, Walecki M, Schäfer M, Kessler M, Zobeiri M, Rinné S, Kiper A, Komadowski M, Vowinkel K, Wemhöner K, Fortmüller L, Schewe M, Dolga A, Fabritz L, Decher N et al |
October, 2018 |
10.1096/fj.201800246R
|